Selecting Binding and Complement-mediated Lysis of Human Hepatoma Cells (PLC/PRF/5) in Culture by Monoclonal Antibodies to Hepatitis B Surface Antigen

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1982 Jan 1

PMID 6952217

Citations 8

Authors

D Shouval

J R Wands

V R Zurawski Jr

K J Isselbacher

D A Shafritz

Affiliations

Soon will be listed here.

Abstract

High-affinity 125I-labelled monoclonal antibodies to hepatitis B virus surface antigen (HBsAg) bind to human hepatocellular carcinoma cell line, PLC/PRF/5, which synthesizes and secretes HBsAg. These monoclonal antibodies of the IgG1, IgG2a, and IgM isotypes are directed against different antigenic determinants on HBsAg and, in the presence of complement, both anti-HBs IgG2a and IgM, but not anti-HBs IgG1, lyse PLC/PRF/5 cells in culture. Although there is a low level of anti-HBs binding (especially with anti-HBs IgM) to human hepatoma cell lines which do not synthesize HBsAg (SK-Hep 1 and Mahlavu cells), this interaction does not lead to complement-mediated cell lysis and is thought to be nonspecific. Minimal binding of 125I-labeled anti-influenza HA antigen IgM binding to PLC/PRF/5 cells was also detected, but this likewise did not lead to complement-mediated cell lysis. These results indicate that a human hepatocellular carcinoma cell line, persistently infected with hepatitis B virus, can be recognized and lysed by monoclonal antibodies directed against specific determinants of HBsAg. Monoclonal antibodies to this viral envelope protein may prove to be useful immunodiagnostic and immunotherapeutic agents when such viral epitopes are expressed on the surface of infected cells.

Citing Articles

Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure.

Gu S, Tang L, Guo L, Zhong C, Fu X, Ye G Emerg Microbes Infect. 2024; 13(1):2409350.

PMID: 39470771 PMC: 11523254. DOI: 10.1080/22221751.2024.2409350.

New Insights into the Role of the Complement System in Human Viral Diseases.

Ostrycharz E, Hukowska-Szematowicz B Biomolecules. 2022; 12(2).

PMID: 35204727 PMC: 8961555. DOI: 10.3390/biom12020226.

B Cell-mediated Humoral Immunity in Chronic Hepatitis B Infection.

Li Y, Yin S, Issa R, Tong X, Wang G, Xia J J Clin Transl Hepatol. 2021; 9(4):592-597.

PMID: 34447690 PMC: 8369012. DOI: 10.14218/JCTH.2021.00051.

Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers.

Hehle V, Beretta M, Bourgine M, Ait-Goughoulte M, Planchais C, Morisse S J Exp Med. 2020; 217(10).

PMID: 32579155 PMC: 7537403. DOI: 10.1084/jem.20200840.

Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Rensen P, de Vrueh R, Van Berkel T Clin Pharmacokinet. 1996; 31(2):131-55.

PMID: 8853935 DOI: 10.2165/00003088-199631020-00005.

References

Ray M, Desmet V, Bradburne A, Desmyter J, Fevery J, De Groote J . Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients. Gastroenterology. 1976; 71(3):462-9. View

Fogh J, Wright W, LOVELESS J . Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst. 1977; 58(2):209-14. DOI: 10.1093/jnci/58.2.209. View

SZMUNESS W . Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978; 24:40-69. View

Omata M, Afroudakis A, Liew C, Ashcavai M, Peters R . Comparison of serum hepatitis B surface antigen (HBsAg) and serum anticore with tissue HBsAg and hepatitis B core antigen (HBcAg). Gastroenterology. 1978; 75(6):1003-9. View

Herlyn M, Steplewski Z, Herlyn D, KOPROWSKI H . Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979; 76(3):1438-42. PMC: 383267. DOI: 10.1073/pnas.76.3.1438. View

Minato N, Bloom B, Jones C, Holland J, Reid L . Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med. 1979; 149(5):1117-33. PMC: 2184868. DOI: 10.1084/jem.149.5.1117. View

Herlyn D, Herlyn M, Steplewski Z, KOPROWSKI H . Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol. 1979; 9(8):657-9. DOI: 10.1002/eji.1830090817. View

Levy R, Dilley J, Fox R, Warnke R . A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci U S A. 1979; 76(12):6552-6. PMC: 411904. DOI: 10.1073/pnas.76.12.6552. View

Kew M, Ray M, Desmet V, Desmyter J . Hepatitis-B surface antigen in tumour tissue and non-tumorous liver in black patients with hepatocellular carcinoma. Br J Cancer. 1980; 41(3):399-406. PMC: 2010221. DOI: 10.1038/bjc.1980.63. View

10.

Hadziyannis S . Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol. 1980; 9(1):117-34. View

11.

Chakraborty P, Ruiz-Opazo N, Shouval D, Shafritz D . Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. Nature. 1980; 286(5772):531-3. DOI: 10.1038/286531a0. View

12.

Aden D, FOGEL A, Plotkin S, Damjanov I, Knowles B . Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979; 282(5739):615-6. DOI: 10.1038/282615a0. View

13.

Wands J, Zurawski Jr V . High affinity monoclonal antibodies to hepatitis B surface antigen (HBsAg) produced by somatic cell hybrids. Gastroenterology. 1981; 80(2):225-32. View

14.

Chisari F, Bieber M, Josepho C, Xavier C, Anderson D . Functional properties of lymphocyte subpopulations in hepatitis B virus infection. II. Cytotoxic effector cell killing of targets that naturally express hepatitis B surface antigen and liver-specific lipoprotein. J Immunol. 1981; 126(1):45-9. View

15.

Gerber M, GARFINKEL E, Hirschman S, Thung S, Panagiotatos T . Immune and enzyme histochemical studies of a human hepatocellular carcinoma cell line producing hepatitis B surface antigen. J Immunol. 1981; 126(3):1085-9. View

16.

Blumberg B, London W . Hepatitis B virus and the prevention of primary hepatocellular carcinoma. N Engl J Med. 1981; 304(13):782-4. DOI: 10.1056/NEJM198103263041312. View

17.

Shouval D, Reid L, Chakraborty P, Ruiz-Opazo N, MORECKI R, Gerber M . Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA. Cancer Res. 1981; 41(4):1342-50. View

18.

Shih J, Cote Jr P, Dapolito G, Gerin J . Production of monoclonal antibodies against hepatitis B surface antigen (HBsAg) by somatic cell hybrids. J Virol Methods. 1980; 1(5):257-73. DOI: 10.1016/0166-0934(80)90023-3. View

19.

Wands J, Carlson R, Schoemaker H, Isselbacher K, Zurawski Jr V . Immunodiagnosis of hepatitis B with high-affinity IgM monoclonal antibodies. Proc Natl Acad Sci U S A. 1981; 78(2):1214-8. PMC: 319978. DOI: 10.1073/pnas.78.2.1214. View

20.

Seeger R, Rosenblatt H, Imai K, Ferrone S . Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res. 1981; 41(7):2714-7. View